A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while stepping up the rigor of inspections on foreign plants.
Trump Orders FDA To Ease US Plant Expansion; Drops Hammer on Foreign Inspections Read More »
The Alchemab deal will further strengthen Lilly’s early-stage pipeline for amyotrophic lateral sclerosis, coming less than a year after the pharma licensed QurAlis’ antisense oligonucleotide to correct a specific protein alteration in ALS.
Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal Read More »
DeSalvo’s last day at the tech giant is Aug. 1. She’ll be replaced by Michael Howell, currently Google’s chief clinical officer.
Karen DeSalvo, Google’s chief health officer, to retire Read More »
The sales are contingent on the closure of UnitedHealth’s acquisition of Amedisys, which has been held up after the Department of Justice sued to block the deal last year.
Biopharma venture capital fundraising declined from $8.1 billion in the first quarter of 2024 to $6.5 billion in the first three months of this year, headlined by a clutch of massive funding rounds.
VC Financings Drop 20% in Q1 but Megarounds Keep Median Deal Size High Read More »
The orthopedics company lowered its earnings forecast, accounting for the tariffs and closing the acquisition of Paragon 28.
Zimmer Biomet expects $60M to $80M tariff impact this year Read More »
Medical device manufacturers could face increased costs if the Commerce Department’s Section 232 probe leads to tariffs on chips.
US semiconductor import probe looms over medtech industry Read More »
Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug.
Vertex Shrugs Off Q1 Miss With ‘Strong’ Journavx Launch, Encouraging Pipeline Position Read More »
Twenty attorneys general allege that the recent workforce reduction at the Department of Health and Human Services is unlawful and could have potentially irreversible consequences.
States Sue RFK Jr., Makary, Seeking to Block HHS Cuts Read More »
In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing investments in the U.S., including Eli Lilly, Johnson & Johnson and Novartis. BMS is the latest to make a multibillion-dollar push.
BMS Pledges $40B Investment in US Despite Cost-Cutting Plans Read More »
